Bullish Case: QiaSymphony Connect launch and FDA clearance of the bloodstream-infection panel support diagnostics momentum; Parse's Federal Circuit win invalidated three 10x patents, and the $4.8M verdict is financially immaterial. Mean-reverting history plus Helium's density mass near $40-45 (0.19-0.23) favors drift back toward $45 if Q3 guidance holds.

Bearish Case: Helium's AI forecast is -5.2% and put volume runs 736% above calls; backwardated term structure with Sep-19 IV >112% at the wings signals event-hedged downside. Willful-infringement finding risks an Evercode injunction, and 10x litigation momentum could reopen downside in single-cell sales.

Potential Outcomes:

1. ~45%: Range $38-44 — mean reversion persists; falsified by a break below $38 on rising put IV.
2. ~20%: Downside $34-38 — adverse injunction or Q3 diagnostics/China miss; falsified by stable margins.
3. ~15%: Upside $45-50 — Q3 beat or hedge unwind; falsified by flat guide into Nov earnings.
4. ~12%: Vol event ±8% around Oct-17/Nov-21 expiries without trend.
5. ~8%: Tail — injunction on Evercode or macro risk-off <$34.

September 15, 2026